These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 39282244)

  • 1. Patient With a Diffuse Large B-Cell Non-Hodgkin Lymphoma in the Right Heart Chamber That Caused Cardiogenic Shock Was Well-Responded to Corticosteroids and Chemotherapy.
    Trung Nguyen K; Van Dang B; Thai Pham D; Viet Tran T; Dinh Le T; Tien Nguyen S; Minh Vu D; Tien Le D; Van Nguyen B; Anh Vu H; Manh Do H; Quang Nguyen H; Ba Ta T; Huy Duong H; Pham Vu Thu H; Duy Nguyen T; Hong Le T; Van Ngo D; Dinh HT; Luong Cong T
    Clin Med Insights Case Rep; 2024; 17():11795476241277663. PubMed ID: 39282244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Rare Case of Diffuse Large B Cell Lymphoma Presenting as a Cardiac Mass.
    Yousif P; Kotecha A; Thakur A; Ismail HM
    Am J Case Rep; 2019 Dec; 20():1821-1825. PubMed ID: 31809493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
    Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
    Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma.
    Shi Y; Zhou P; Han X; He X; Zhou S; Liu P; Yang J; Zhang C; Gui L; Qin Y; Yang S; Zhao L; Yao J; Zhang S
    Chin J Cancer; 2015 Sep; 34(11):522-30. PubMed ID: 26370464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
    Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
    Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
    Davies A; Cummin TE; Barrans S; Maishman T; Mamot C; Novak U; Caddy J; Stanton L; Kazmi-Stokes S; McMillan A; Fields P; Pocock C; Collins GP; Stephens R; Cucco F; Clipson A; Sha C; Tooze R; Care MA; Griffiths G; Du MQ; Westhead DR; Burton C; Johnson PWM
    Lancet Oncol; 2019 May; 20(5):649-662. PubMed ID: 30948276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant lymphoma consisting of mediastinal large B-cell lymphoma and nodular sclerosis Hodgkin lymphoma in the right supraclavicular lymph nodes: a case report.
    Zhang C; Yi Y; Chen C; Wang J; Liu Z
    Diagn Pathol; 2015 Dec; 10():215. PubMed ID: 26715530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Primary Mediastinal B-Cell Lymphoma With R-CEOP (Rituximab, Cyclophosphamide, Etoposide, Vincristine, and Prednisone).
    Cherukuri SV; Sureen A; Infante T; Rajendran N; Padilla O; Gaur S
    Cureus; 2021 Jul; 13(7):e16128. PubMed ID: 34350085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse Large B-cell Lymphoma Presenting as a Cardiac Mass.
    Nasir A; Patel YB
    Cureus; 2024 May; 16(5):e59755. PubMed ID: 38840985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Curious Case of Pericardial Effusion Diagnosed as Diffuse Large B-cell Lymphoma.
    Mahashabde ML; Bhavsar HM; Bhimani YR
    Cureus; 2024 Aug; 16(8):e65991. PubMed ID: 39221368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial.
    Davies A; Barrans S; Burton C; Mercer K; Caddy J; Chinnery F; Day L; Fernando D; Ardeshna K; Collins G; Radford J; Rule S; McMillan A; Johnson P; Griffiths G
    F1000Res; 2020; 9():941. PubMed ID: 33093947
    [No Abstract]   [Full Text] [Related]  

  • 16. Primary cardiac lymphoma: a case report.
    Ellen S; Emma H
    Eur Heart J Case Rep; 2023 Apr; 7(4):ytad175. PubMed ID: 37090756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature.
    Oumeish OY; Oumeish I; Tarawneh M; Salman T; Sharaiha A
    Int J Dermatol; 2006 Mar; 45(3):306-10. PubMed ID: 16533236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: A long-term survival case of diffuse large B-cell lymphoma with left ventricular infiltration and spinal cord compression.
    Sun R; Jin C; Qin H; Zhang W; Ning Z; Liu J; Wang A
    Front Cardiovasc Med; 2023; 10():1309613. PubMed ID: 38173814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with doxorubicin-based protocol in cardiac involvement diffuse large B-cell lymphoma: A case report.
    Tekinalp A; Kars TU; Dikici HZ; Yılmaz PD; Demircioğlu S; Çeneli Ö
    J Oncol Pharm Pract; 2022 Mar; 28(2):449-452. PubMed ID: 34549658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Primary renal lymphoma: a clinical analysis of 5 cases].
    Lu L; Shi HZ; Xiao ZJ; Wang D; Li CL
    Zhonghua Yi Xue Za Zhi; 2018 May; 98(18):1443-1445. PubMed ID: 29804410
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.